HEALEY ALS Platform Trial - Regimen B Verdiperstat
Status:
Enrolling by invitation
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial
evaluating the safety and efficacy of investigational products for the treatment of ALS.
Regimen B will evaluate the safety and efficacy of a single study drug, verdiperstat, in
participants with ALS.